

FORM PTO-1390

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER

10806-130

U.S. APPLIC. NO. (if known, see 37 CFR
1.5)**09/582808**

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/SE98/02462	30 DECEMBER 1998	30 DECEMBER 1997

TITLE OF INVENTION

ANALYTICAL METHOD USING PARTICLES AND TEST KIT FOR PERFORMING THE METHOD

APPLICANT(S) FOR DO/EO/US

MENDEL-HARTVIG, Ib; VINTERBÄCK, Lena; JONSSON, Ann; GUSTAFSSON, Jörgen

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau (22 July 1999).
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US)
6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendment has NOT expired.
 - d. have not been made and will not be made.
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
 A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information: Copy of published International application, including Search Report


CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label #: EL343337385US

Date of Deposit: 30 June 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box PCT; Assistant Commissioner for Patents; Washington, DC 20231.

526 Rec'd PCT/PTO 30 JUN 2000

U.S. APPLIC. NO. (if known, see 37 CFR 1.50) 09/582808	INTERNATIONAL APPLICATION NO. PCT/SE98/02462	ATTORNEY'S DOCKET NUMBER 10806-130										
		CALCULATIONS PTO USE ONLY										
<p>17. The following fees are submitted:</p> <p>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</p> <table> <tr> <td><input type="checkbox"/> Search Report has been prepared by the EPO or JPO</td> <td>\$840.00</td> </tr> <tr> <td><input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482)</td> <td>\$670.00</td> </tr> <tr> <td><input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))</td> <td>\$760.00</td> </tr> <tr> <td><input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO</td> <td>\$970.00</td> </tr> <tr> <td><input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)</td> <td>\$96.00</td> </tr> </table> <p style="text-align: center;">ENTER APPROPRIATE BASIC FEE AMOUNT =</p>		<input type="checkbox"/> Search Report has been prepared by the EPO or JPO	\$840.00	<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482)	\$670.00	<input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))	\$760.00	<input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$970.00	<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)	\$96.00	
<input type="checkbox"/> Search Report has been prepared by the EPO or JPO	\$840.00											
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482)	\$670.00											
<input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))	\$760.00											
<input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$970.00											
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)	\$96.00											
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 130.00										
Claims	Number Filed	Number Extra	Rate									
Total Claims	41 -20 =	21	x \$18.00	\$ 378.00								
Independent Claims	3 -3 =	0	x \$78.00	\$								
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$								
		TOTAL OF ABOVE CALCULATIONS =	\$1478.00									
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).			\$									
		SUBTOTAL =	\$1478.00									
Processing fee of \$130.00 for furnishing the English translation later than the <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+ \$	\$									
		TOTAL NATIONAL FEE =	\$1478.00									
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		+ \$	\$									
		TOTAL FEES ENCLOSED =	\$1478.00									
		Amount to be: refunded	\$									
		charged	\$									
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$1,478.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 04-1133.</p>												
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>												
SEND ALL CORRESPONDENCE TO:  HOLLY D. KOZLOWSKI NAME 30,468 REGISTRATION NUMBER 30 JUNE 2000 DATE												
BASED ON FORM PTO-1390 (Rev. 5-93)												
577934.01												

09/582808
526 Rec'd PCT/PTO 30 JUN 2000

Docket No. 10806-130

PATENT

CERTIFICATE OF MAILING

"Express Mail" mailing label #: EL343337385US

Date of Deposit: June 30, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box PCT; Assistant Commissioner for Patents; Washington, DC 20231.

Cathleen L. Vigin

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Ib MENDEL-HARTVIG et al : Paper No.:

Based On: PCT/SE98/02462 : Group Art Unit:

Filing Date: June 30, 2000 : Examiner:

For: **Analytical Method Using Particles and Test Kit for Performing the Method**

PRELIMINARY AMENDMENT

BOX PCT
Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Prior to calculation of the filing fee and first action by the Examiner, please amend the present application as follows:

In the Claims:

Please amend claims 1-34 as follows:

1. (Amended) A method associated with analytical methods in a flow matrix, which analytical methods utilize biospecific affinity reactions to detect an analyte in a sample, the method comprising [and which comprises]:

i. allowing the sample (analyte) and an analytically detectable reactant

(Reactant*) to migrate through flow channels in a flow matrix to a detection zone (DZ)

located in the matrix, in which there is a firmly anchored biospecific affinity reactant (Capturer), [wherein] and

- ii. capturing Reactant* [is captured] in the detection zone (DZ) in an amount, being related to the amount of analyte in the sample,
[characterized in that] wherein
- A) Reactant* has particles as an analytically detectable group, and
B) the Capturer is anchored to the matrix via immobilized particles[, which preferably exhibit hydrophilic groups on their surface].

Claim 2, line 1, replace “characterized in that” with --wherein--.

Claim 3, lines 1-2, replace “or 2, characterized in that” with --, wherein--

4. (Amended) The method according to claim 1, wherein [any of the claims 1-3, characterized in that] the Capturer is capable of binding via biospecific affinity a reactant which in turn binds analyte biospecifically.

Claim 5, line 1, replace “characterized in that” with --wherein--.

6. (Amended) The method according to claim 1, wherein [any of claims 1-5, characterized in that] the particles anchoring the Capturer have a size which is smaller than [the] a smallest inner dimension of the flow channels of the matrix.

7. (Amended) The method according to claim 1, wherein [any of claims 1-6, characterized in that] the particles, which anchor the Capturer, have a size [being] in the range of 0.1-1000 µm[, preferably the range of 0.1-100 µm].

8. (Amended) The method according to claim 1, wherein [any of claims 1-7, characterized in that] the label particles have a diameter in the range of 0.01-5 µm.

9. (Amended) The method according to claim 1, wherein [any of claims 1-8, characterized in that] the flow channels have [the] a smallest inner dimension in the range of 0.4-1000 µm[, preferably 0.4-100 µm].

10. (Amended) The method according to claim 1, wherein [any of claims 1-9, characterized in that] the label particles are fluorescent or coloured.

11. (Amended) The method according to claim 1, wherein [any of claims 1-10, characterized in that] Reactant* is predeposited in the matrix upstream of the detection zone (DZ) [and preferably upstream of the sample application site].

12. (Amended) The method according to claim 1, wherein [any of claims 1-11, characterized in that] the particles, which anchor the Capturer to the matrix, are a synthetic polymer, [or] a semisynthetic polymer or a biopolymer which on its surface exhibits hydrophilic groups.

13. (Amended) The method according to claim 1, wherein [any of claims 1-12, characterized in that] the determination method is of sandwich type in which Reactant* is captured in the detection zone (DZ) by formation of the ternary complex Reactant'---analyte---Reactant*, and wherein Reactant' and Reactant* are able to simultaneously bind analyte biospecifically and Reactant' is the firmly anchored Capturer or a reactant to which the Capturer may bind via biospecific affinity.

14. The method according to claim 13, [characterized in that] wherein the analyte is an antibody with specificity for either Reactant' or Reactant*, and [that] wherein

- a) Reactant' is an antigen/hapten and Reactant* is an antibody directed to a constant antibody region on the analyte, when the antibody specificity of the analyte is directed to Reactant', or
- b) Reactant* is an antigen/hapten and Reactant' is an antibody directed to a constant antibody region on the analyte, when the antibody specificity of the analyte is directed to Reactant'.

Claim 15, line 1, replace “characterized in that” with --wherein--.

16. (Amended) The method according to claim 13, wherein [any of the claims 13-14, characterized in that] the analyte is of IgE class directed to an allergen.

17. (Amended) The method according to claim 1, wherein [any of the claims 1-16, characterized in that] the determination method is performed in connection with diagnosing allergy or autoimmune disease.

18. (Amended) A test kit for performing analytical methods in a flow matrix, which analytical methods utilize biospecific affinity reactions to detect an analyte in a sample, which kit comprises (i) a flow matrix having a detection zone (DZ), in which there is a firmly anchored biospecific affinity reactant (Capturer), and (ii) an analytically detectable reactant (Reactant*), wherein

- A) Reactant* has particles as an analytically detectable group, and
- B) the Capturer is anchored to the matrix via immobilized particles[, which preferably exhibit hydrophilic groups on their surface].

Claim 19, line 1, replace “characterized in that” with --wherein--.

Claim 20, lines 1-2, replace “or 19, characterized in that” with --, wherein--.

21. (Amended) A kit according to claim 18, wherein [any of the claims 18-20, characterized in that] the Capturer is capable of binding via biospecific [biospecific] affinity a reactant which in turn binds analyte biospecifically.

Claim 22, line 1, replace “characterized in that” with --wherein--.

23. (Amended) The kit according to claim 18, wherein [any one of claims 18-22, characterized in that] the particles anchoring the Capturer have a size which is smaller than [the] a smallest inner dimension of the flow channels of the matrix.

24. (Amended) The kit according to claim 18, wherein [any of the claims 18-23, characterized in that] the particles, which anchor the Capturer, have a size [being] in the range of 0.1-1000 µm[, preferably the range of 0.1-100 µm].

25. (Amended) The kit according to claim 18, wherein [any of the claims 18-24, characterized in that] the label particles have a diameter in the range of 0.01-5 µm.

26. (Amended) The kit according to claim 18, wherein [any of the claims 18-25, characterized in that] the flow channels have [the] a smallest inner dimension in the range of 0.4-1000 µm[, preferably 0.4-100 µm].

27. (Amended) The kit according to claim 18, wherein [any of the claims 18-26, characterized in that] the label particles are fluorescent or coloured.

28. (Amended) The kit according to claim 18, wherein [any of the claims 18-27, characterized in that] Reactant* is predeposited in the matrix upstream of the detection zone (DZ) [and preferably upstream of the sample application site].

29. (Amended) The kit according to claim 18, wherein [any of the claims 18-28, characterized in that] the particles, which anchor the Capturer to the matrix, are a synthetic polymer, [or] a semisynthetic polymer or a biopolymer which on its surface exhibits hydrophilic groups.

30. (Amended) The kit according to claim 18, wherein [any of the claims 18-29, characterized in that] the kit is [intended for] operable in a determination method of sandwich type in which Reactant* is captured in the detection zone (DZ) by formation of the ternary complex Reactant'---analyte---Reactant*, and wherein Reactant' and Reactant* are able to simultaneously bind analyte biospecifically and Reactant' is the firmly anchored Capturer or a reactant to which the Capturer may bind via biospecific affinity.

31. (Amended) The kit according to claim 30, [characterized in that] wherein the analyte is an antibody with specificity for either Reactant' or Reactant*, and [that]

- a) Reactant' is an antigen/hapten and Reactant* is an antibody directed to a constant antibody region on the analyte, when the antibody specificity of the analyte is directed to Reactant', or
- b) Reactant* is an antigen/hapten and Reactant' is an antibody directed to a constant antibody region on the analyte, when the antibody specificity of the analyte is directed to Reactant*.

Claim 32, line 1, replace “characterized in that” with --wherein--.

Claim 33, lines 1-2, replace “or 31, characterized in that” with --, wherein--.

34. (Amended) The kit according to claim 18, wherein the kit is operable in a [any of the claims 18-33, characterized in that the] determination method [is] performed in connection with diagnosing allergy or autoimmune disease.

Please add the following claims 35-41:

--35. (NEW) The method according to claim 1, wherein the immobilized particles exhibit hydrophilic groups on their surface.--

--36. (NEW) The method according to claim 7, wherein the particles have a size in the range of 0.1-100 μm .--

--37. (NEW) The method according to claim 9, wherein the flow channels have a small inner dimension in the range of 0.4-100 μm .--

--38. (NEW) The method according to claim 11, wherein the Reactant* is predeposited in the matrix upstream of the sample application site.--

--39. (NEW) The kit according to claim 18, wherein the immobilized particles exhibit hydrophilic groups on their surface.--

--40. (NEW) The kit according to claim 24, wherein the particles have a size in the range of 0.1-100 μm .--


--41. (NEW) The kit according to claim 26, wherein the flow channels have a small inner dimension in the range of 0.4-100 μm .--

REMARKS

By the present Amendment, the claims are amended to omit their multiple dependency and for various matters of form in accordance with customary U.S. patent practice. Claims

35-41 are added and contain limitations from original claims 1, 7, 9, 11, 18, 24 and 26, respectively. Since these changes do not involve any introduction of new matter, entry is believed to be in order and is respectfully requested.

Respectfully submitted,



Holly D. Kozlowski
Reg. No. 30,468
Dinsmore & Shohl LLP
1900 Chemed Center
255 East Fifth Street
Cincinnati, Ohio 45202
(513) 977-8568

577942.01

ANALYTICAL METHOD USING PARTICLES AND TEST KIT FOR
PERFORMING THE METHOD

Technical field

5 The invention relates to determination methods utilizing biospecific affinity reactions in combination with an analytically detectable reactant (Reactant*) to determine an analyte in a sample. The methods involve utilizing matrices surrounding a liquid flow, which transports
10 analyte and reactants to a detection zone (DZ) in/on the matrix. In the detection zone there is a biospecific affinity reactant (Capturer) firmly anchored to the matrix, which allows for a complex (containing Reactant* and the Capturer) to be formed in the detection zone in an amount
15 reflecting the amount of analyte in the sample. The invention also relates to a test kit for performing the method.

By reactants (including the analyte), exhibiting
20 biospecific affinity (bioaffinity reactants) and which therefore may be utilized in the invention, are meant individual members of the reactant pairs: antigen/hapten - antibody; biotin-avidin/streptavidin; two complementary single chains of nucleic acid etc. As antibodies, antigen
25 binding antibody fragments such as Fab, F(ab)₂', single chain Fv (scFv) antibodies etc. are considered. Relevant reactants do not have to be naturally occurring but may also be synthetically prepared molecules/binders.

30 The type of test methodology in question has previously been used primarily for biospecific affinity reactants where at least one part in a utilized reactant pair has exhibited protein structure, in particular in connection with so called immunochemical determination methods.

35 The biospecific affinity reactions are primarily performed in aqueous media (e.g. water).

Previously used technique

It is previously known how to anchor Capturer to the relevant type of matrices. An alternative has been to 5 achieve this via particles, which have been deposited in/on the matrix. The Capturer has in turn been bound to the particles via bonds which are stable under the conditions used to capture a Reactant* in the detection zone. The bond between Capturer and particle has commonly been covalent 10 but also physical and biospecific adsorption may have been utilized. See inter alia Abbott/Syntex US 4,740,468; Abbott EP 472,476; Hybritech EP 437,287 and EP 200,381; Grace & Co. EP 420,053; Fuji Photo Film US 4,657,739; Boehringer Mannheim WO 94/06012. Label groups suitable to utilize for 15 Reactant* in the relevant type of tests are well known, e.g. particles (Pharmacia AB WO 96/22532; Unilever WO 88/08534; Abbott Laboratories US 5,120,643, Becton Dickinson EP 284,232 etc.). The combination of particles as detectable group and as anchoring particles is also known 20 from several of the publications mentioned above. See e.g. Boehringer Mannheim EP 462,376.

Disadvantages of previous technique and aim of the invention

25 In connection with previously known determination methods of the type initially mentioned, there has often been a need for improved detection sensitivity. There has also often been desirable with systems which are easier to produce.

30 The invention aims at improvements concerning these problems.

The invention

35 We have now discovered that anchoring of the Capturer via particles, preferably being smaller than the smallest inner dimension of the flow channels in a flow matrix, is working

surprisingly well together with Reactant*, in which the analytically indicatable group is particles. Thus the invention is a test methodology according to what initially has been said and is characterized in that:

5

- A) The analytically detectable reactant (Reactant*) as label group has particles, and
 - B) The Capturer is anchored to the matrix via particles, having such dimensions that they as such could be
- 10 transported in the flow passing through the matrix.

The particles should, especially when they are smaller than the flow channels in the matrix, on their surface preferably exhibit hydrophilic groups, which do not belong 15 to the biospecific affinity reactant bound to the particles. Preferred hydrophilic groups are uncharged (usually in the form of alcoholic hydroxyl groups).

In principle, the label particles and anchoring particles 20 may be of the same type, only observing that the anchoring particles do not interfere with the detection of Reactant* in the detection zone.

Particles, intended for anchoring of Capturer in DZ, 25 should, as mentioned above, preferably be smaller than the smallest inner dimension of the flow channels. Suitable particle sizes (largest outer dimension/diameters) are in the interval 0.1-1000 µm, preferably 0.1-100 µm.

Considerations must be made in every special case regarding 30 the smallest inner dimension of the flow channels in the matrix to be used. The particles used may be polydisperse or monodisperse. Their shape may vary from spherical to totally irregular. Suitable particle materials which can be mentioned are e.g. SiO₂ and other polymeric materials such 35 as organic polymers chosen among

- (a) synthetic polymers, e.g. condensation polymers, addition polymers etc. Among addition polymers can

particularly be mentioned those based on monomers chosen among alkylvinyl ether, arylvinyl ether, vinylarene (such as styrene and divinyl benzene), alkylalkene, acrylate, methacrylate, acrylamide, 5 methacrylamide etc., and

- (b) biopolymers, e.g. polysaccharides (agarose, dextran, starch) optionally being synthetically cross-linked (an example of semi-synthetic polymer) etc.

10

In this connection so called latex particles have often been used, which often are polymerized styrene or other polymerized alkene/alkadiene. The anchoring particles may be porous or non-porous.

15

It is often important to choose anchoring particles being intermediate regarding hydrophobic and hydrophilic features. The reason is that the flow matrices in question often exhibit a marked hydrophobicity although they are 20 sufficiently hydrophilic for allowing a flow of aqueous liquid media. A marked hydrophobic particle, e.g. of polystyrene, is thus adsorbed very strongly to nitrocellulose membranes. The same can also be said for other flow matrices with comparable balance between 25 hydrophilic and hydrophobic features. Unfortunately hydrophobic features of the particles promote non-specific adsorption of Reactant* and/or analyte. This decreases the sensitivity of the test methodology. In our systems we therefore chose to hydrophilize hydrophobic particles, e.g. 30 by on their surface introducing hydrophilic groups, such as hydroxy groups. It is particularly convenient to coat hydrophobic particles with polyhydroxy polymers or other hydrophilic polymers, which preferably should be substituted with hydrophobic groups, e.g. hydrocarbyl 35 groups such as phenyl. As specific examples of usable hydrocarbyl substituted hydrophilic polymers, those having polysaccharide structure, e.g. phenyldextran can be mentioned. Presence of the hydrophobic groups on a

SEARCHED
INDEXED
COPIED
FILED

hydrophilic polymer facilitates the adsorption of the polymer to hydrophobic particles. This decreases in turn the need of stabilising an adsorbed polymer via cross-linking. In industrial engineering this may be of great importance as cross-linking easily leads to particle aggregation, especially for the particles having the small dimensions often used in connection with the present invention. Introduction of hydrophilic groups on the particles means that covalent binding of biospecific affinity reactants to the particles more easily can be achieved. Also hydrophilisation as such decreases the tendency of non-specific adsorption in the detection zone.

Particles intended for Reactant* to be detectable are usually smaller than those utilized for anchoring. Suitable particle diameters are usually chosen in the interval 0.001-5 µm, often preferably colloidal dimensions, so called sol (i.e. spheric and monodisperse with a size in the interval 0.001-1 µm). In principle the same particle material as for the anchoring particles may be used. Well known label particles are metal particles (e.g. gold sol), non-metal particles (SiO_2 , carbon, latex (polystyrene) and killed erythrocytes and bacteria). For particles of non-colloidal dimensions it is true that they should be non-sedimentary under the conditions which are valid for transport in the matrix. Thus carbon particles (< 1 µm), which have been more or less irregular and more or less polydisperse, have been used (Pharmacia AB, WO 96/22532). The particles may be provided with groups facilitating their detection, e.g. by being provided with chromophore, fluorophore, radioactive compound, enzyme etc. In the invention it has been shown to be unexpectedly advantageous with fluorescent particles rather than coloured particles, such as carbon particles.

The demands for balance between hydrophobic and hydrophilic features for label particles are similar to those being true for the anchoring particles.

- 5 When the Capturer with its anchoring particles is deposited in the detection zone it is essential that the conditions are chosen so that physical adsorption to the matrix is promoted. Drying is often essential. When the bonds between matrix and anchoring particles once have been formed it is
10 often difficult to break them. However Reactant* shall be applied under conditions promoting the reactant to be maintained in suspension and does not promote physical adsorption of the particles to the matrix. If Reactant* is to be predeposited in the matrix it is essential that it is
15 made in a way which promotes rapid resuspension for transport in the matrix. Compare below under the heading "Application zone for biospecific affinity reactants other than analyte (A_RZ)".
- 20 In the detection zone, the analyte may bind directly or indirectly to the Capturer. In the last-mentioned case the Capturer is a biospecific affinity reactant which can bind to an additional reactant which in turn binds to the analyte via biospecific affinity. In this case this
25 additional reactant need not be immobilized in the matrix from the beginning, but may be movably (diffusively) pre-deposited in the matrix in an area or zone separated from the detection zone, or it may be added together with or separately from the sample. If this additional reactant is
30 in soluble form, the Capturer is advantageously one member of a specific binding pair, the other member of which is coupled or conjugated to the reactant. Examples of such specific binding pairs are immunological binding pairs, such as antigen-antibody and haptens-antibody, biotin-avidin
35 or -streptavidin, lectin-sugar, nucleic acid duplex.

The particle system according to the invention is particularly advantageous for allergy tests, where the

allergen with which the analyte (most often of IgE class) is to react usually is a complex mixture of up to 100 or even more different proteins. By covalent coupling of the proteins to particles and predeposition thereof, a very 5 robustly immobilized allergen is obtained, which allergen in contrast to allergen which is passively adsorbed to a matrix does not leak selectively more of certain components. This in combination with the fact that particle labels give a very good signal results in an extraordinary 10 test system for allergy. The above applies to all tests where complex binders are used, e.g. autoantigens in the determination of autoimmune disease.

A variant with soluble reactant (allergen) which is pre- 15 deposited or is added together with the sample may also give other advantages in allergy tests, since on the one hand, the incubation time between particle label and allergen/analyte will be considerably longer, and, on the other hand, a soluble allergen is more available for 20 reaction with the analyte than when the allergen is bound to a solid phase.

Matrices

25 The matrix defines the space in which the reactants are transported. The matrix may be the inner surface of a single flow channel (e.g. a capillary), the inner surface of a porous matrix having a system of flow channels extending through, etc. This type of matrices is called 30 flow matrices below. Flow matrices may exist in the form of monoliths, sheets, columns, membranes, single flow channels having capillary dimensions or aggregated systems of such flow channels etc. They may also exist in the form of particles packed in column casings, compressed fibres etc. 35 The inner surface of the matrices should be hydrophilic, so that aqueous media (usually water) may be absorbed and transported through the matrices. The smallest inner dimension of the flow channels should be sufficiently large

for allowing transport through the matrix of the reactants used. The rule of thumb is that suitable matrices are selectable among those having flow channels with the smallest inner dimension in the interval 0.4-1000 µm,

5 preferably 0.4-100 µm if the matrix has a system of mutually communicating flow channels. Flow channels having the smallest inner dimension in the upper part of the broad interval (up to 1000 µm) are primarily of interest for flow driven by an externally applied pressure/sucking.

10

Matrices of interest are often built up from a polymer, e.g. nitrocellulose, nylon etc. The material in the matrix as well as the physical and geometrical design of the flow channels may vary along the flow depending on what a
15 certain part of the matrix is to be utilized for (Pharmacia AB WO 96/22532; Medix WO 94/15215).

Along the transport flow in the matrix there may be defined zones for application of sample (A_sZ), reactants (A_rZ),
20 buffer (A_bZ), etc. and zones for detection (DZ) and calibrator (CZ, see below).

Flow matrices, which may be used in the particular type of tests, are described in previous patent publications
25 (Behringwerke US 4.861.711; Unilever WO 88/08534; Abbott US 5.120.643 and US 4.740.468; Becton Dickinson EP 284.232 and US 4.855.240; Pharmacia AB WO 96/22532 etc.).

Transport flow

30 The direction of the transport flow is from an application zone towards a detection zone (DZ). Exactly which zones the transport flow will pass is determined by the particular test protocol. A transport flow may start from a point with radial spread and a flow front in the form of a circular
35 periphery or a part thereof. A transport flow may also start from a zone in the form of a band and may have a straight flow front perpendicular to the direction of flow.

In a less preferred variant the transport flow proceeds from an application zone for sample, which at the same time is a zone for detection. The flow in this variant is spread 5 out from the application/detection zone, preferably radially, and may possibly pass additional downstream detection zones.

The transport flow through the particular types of matrix 10 may be achieved by influence of capillary forces, e.g. by starting off with a substantially dry matrix. As an aid a sucking body may be placed at the end of the flow. Flow, meaning transport mainly only of dissolved components, may be achieved if an electrical field is imposed across the 15 matrix (in the flow direction).

The utilized flow is preferably lateral, i.e. parallel with the upper surface of the matrix. Also other types of flow (in depth in the matrix) may be used.

20

Relevant test protocols

The invention may primarily be applied to non-competitive (non-inhibition) test variants but also to competitive (inhibition) test variants. The complexes being formed in 25 different test protocols are described schematically below. It has been assumed that relevant reactants are monovalent regarding utilized binding sites. The protocols may be run as simultaneous or sequential variants regarding analyte and an added reactant. By simultaneous variants is meant 30 that the analyte (sample) and the reactant in question migrate together at least during some part of the transport and preferably reach the detection zone simultaneously. By sequential variants is meant that the analyte (sample) at least during some part of the transport towards the 35 detection zone migrates before a reactant and preferably reaches the detection zone before the reactant. The test protocols of the invention should always be simultaneous or sequential regarding analyte and Reactant*. "--" relates to


10

firm anchoring from the start. "---" relates to binding via biospecific affinity.

A. Sandwich protocol:

- 5 Capturer and Reactant* have biospecific affinity for the analyte. x is the number of moles of Capturer on the matrix. y is the number of moles of analyte (= the number of moles of Reactant*), being bound to the Capturer.


10 Complex formed in the detection zone:



B. Sandwich protocol:

- The Capturer has biospecific affinity for Reactant I, which
15 in turn has biospecific affinity for the analyte. Reactant*
has biospecific affinity for the analyte. x is the number
of moles of Capturer on the matrix. y is the number of
moles of analyte (= the number of moles of Reactant*),
being bound to the Capturer via Reactant I. y + z is the
20 number of moles of Reactant I being bound to Capturer.

Complex formed in the detection zone:



25

C. Inhibition protocol:

The Capturer is an analyte analogue and has binding sites equivalent to binding sites on the analyte. Reactant II has biospecific affinity to the analyte and to Capturer.

- 30 Reactant* has biospecific affinity to Reactant II. x is the number of moles of Capturer on the matrix. y is the number of moles of Reactant II (= the number of moles of Reactant*), being bound to the matrix via Capturer.
Reactant II is part of the complex in an amount related to
35 the amount of analyte in the sample.

Complex formed in the detection zone:

Matrix(-Capturer)_{x-y}(-Capturer---Reactant II---Reactant*)_y.

D. Inhibition protocol:

The Capturer exhibits biospecific affinity for both analyte
5 and Reactant*. Reactant* is a detectable soluble analyte
analogue. x and y are the number of moles of Reactant* and
analyte respectively, being bound to the matrix via
Capturer. x + y is the number of moles of Capturer on the
matrix.

10

Complex formed in the detection zone:

Matrix(-Capturer---Reactant*)_x(-Capturer---analyte)_y.

15 **Application zone for sample (A_sZ)**

This type of zone is to be found upstream of the detection
zones for the intended analyte.

Application zone for biospecific affinity reactants other

20 **than analyte (A_RZ)**

The sequence of the application zones should ensure that
the test protocols are simultaneous or sequential regarding
analyte and Reactant*. This means that the application zone
for reactants (A_RZ), inclusive for Reactant* ($A_{R*}Z$), should
25 always be upstream of the detection zone. One or more
reactants may be added in the same application zone. If the
application zone is common to sample and at least one
reactant (= A_RZ/A_sZ), e.g. Reactant* (= $A_{R*}Z/A_sZ$), application
may be performed simultaneously, e.g. that a sample and
30 reactant are mixed before being applied in the zone. If
desired the mixture may be pre-incubated so that the
reactant binds in an intended way to the analyte or other
components in the sample before application. One skilled in
the art may with knowledge of different protocols easily
35 determine which zones will be needed and in which order
they are to be positioned.

Reactants being utilized in the method may be pre-deposited in the respective zone or be added when the determination method is performed. Pre-deposition means that the reactant in question is applied in advance and in such a way that it 5 does not spread in the matrix until flow is initiated.

Pre-deposition of reactants may take place by methods known per se. (See e.g. Behringwerke US 4.861.711; Unilever WO 88/08534; Abbott US 5.120.643; Becton Dickinson EP 10 284.232). It is important to take into consideration that the reactant in question should be able to dissolve when a liquid reaches a predeposited reactant. To ensure quick dissolution it is common to incorporate relevant reactants in substances being quickly dissolved by contact with the 15 liquid medium used. This type of substances are often hydrophilic having polar and/or charged groups, such as hydroxy, carboxy, amino, sulphonate etc. In particular may be mentioned hydrophilic quickly soluble polymers, e.g. having carbohydrate structure, simple sugars including 20 mono-, di- and oligosaccharides and corresponding sugar alcohols (mannitol, sorbitol etc.). It is common practice to first coat the relevant application zone with a layer of the quickly soluble substance, and then the reactant is applied, optionally followed by an additional layer of 25 quickly soluble substance. An alternative way is to incorporate the reactant in particles of quickly soluble material which then are deposited in the relevant zone of the matrix.

30 **Zones for buffer (A_bZ)**

Essential buffer systems may be included in solutions added simultaneously with samples and reactants. In conventional technique addition of buffer takes place in the application zone upstream of the other application zones. This has 35 usually been equal to sample application zone. In the present invention application of buffer may be performed in optional position (see below).

In a co-pending PCT application "Analytical method comprising addition in two or more positions and a device and test kit therefor" (based on SE 9704934-0) we describe an invention which in one variant provides a preferred embodiment of the present invention. The patent application is incorporated herein by reference. The invention in this separate patent application is based upon the discovery that liquid from two subsequent zones (AZ2 and AZ1) in a flow matrix may migrate after each other without being mixed, if liquid is applied to the downstream zone (AZ1) simultaneously or before applying liquid to the upstream zone. This has led to the possibility to achieve zonewise migration of optional reactants, included in the liquids, towards a detection zone. If the application zone for sample (A_sZ) is placed downstream of the application zone for Reactant* ($A_{R*}Z$), the test protocol becomes sequential regarding Reactant*. Having an application zone only for liquid (buffer) (A_bZ) between ($A_{R*}Z$) and (A_sZ) a wash of the detection zone DZ is performed between capture of analyte and capture of Reactant*. Such an intermediate buffer zone (A_bZ) may also ensure that a reactant (including analyte), that is applied in a downstream zone, reaches DZ before a reactant, starting from an upstream application zone for liquid. The latter may be important if the matrix as such retards the reactant that has been applied in the downstream zone.

Reactants may be included in the liquid that is applied to a zone. Alternatively, they may be predeposited in the zone where the corresponding liquid is to be applied or in a zone positioned between this and the nearest downstream zone for application of liquid.

This separate invention allows for application of buffer in the present invention to be performed in optional position. According to conventional technique addition of buffer has only been possible in the application zone, upstream of the other application zones.

This embodiment of the invention is particularly interesting for methods being sequential regarding Reactant*.

5

Analytes

The invention is primarily adapted for determination of biospecific affinity reactants of the types initially mentioned. The analyte may be a cell or a virus or a part 10 thereof. In particular antigen may be mentioned, such as an immunoglobulin or an antibody. For immunoglobulins the determination may relate to a certain Ig and/or a certain Ig subclass. For antibody the determination may relate to a certain specificity, optionally also the Ig class or Ig 15 subclass of the antibody. Relevant Ig classes are IgA, IgD, IgE, IgG and IgM. Relevant Ig subclasses are IgG1, IgG2, IgG3 and IgG4.

- In sandwich variants (according to protocols A and B above) 20 the analyte may be an antibody, directed to an allergen/antigen/hapten, and derive from a certain species, a certain Ig class or a certain Ig subclass. In this case Reactant* may be an analytically detectable antibody directed to an epitope being specific for the species, Ig 25 class or Ig subclass with Capturer (protocol A) and Reactant I (protocol B) as the allergen/antigen/hapten. Alternatively the reverse is chosen i.e. Capturer and Reactant I, respectively, is the antibody directed to the analyte. In the case where the analyte is an antigen in 30 general, for protocol A both the Capturer and Reactant* may be antibodies directed to the antigen. For protocol B it is Reactant I and Reactant* that are antibodies directed to the antigen.
- 35 Competitive variants are the most interesting for low molecular analytes. Illustrative examples are antigen and hapten. For protocol C the Capturer may be the antigen or the hapten, firmly anchored to the matrix, Reactant II may

be an antibody, directed to the antigen, and Reactant* may be an antibody directed to Reactant II. For protocol D the Capturer may be an antibody directed to the analyte and Reactant* may be the analyte labelled with an analytically detectable group.

The method of the invention may be performed as part of diagnosing allergy or autoimmune disease.

It has been particularly interesting for the inventors to measure anti-allergen antibodies of IgE or IgG class, for the latter preferably with emphasis on some of the mentioned subclasses. Measurement of allergen-specific antibodies may be utilized in connection with diagnosing of IgE mediated allergy.

The invention has, as already mentioned above, proved to be particularly suitable in the case where the Capturer consists of a mixture of different components, e.g.

allergen, which often consist of mixtures of several different allergenic components and where the analyte is antibodies directed to individual components in the mixture.

25 Samples

Relevant samples may be of biological origin, e.g. from different body fluids (whole blood, serum, plasma, urine, tear fluid, cerebrospinal fluid etc.), from cell culture media, processing procedures in biotechnology, from food stuff, from the environment (environment analysis samples) etc. The samples may be pre-treated in order to fit e.g. the matrix, the test protocol involved etc.

Calibrators

Determination methods of the type to which the invention relates involves measurement of the detectable signal from the analytically detectable reactant (Reactant*) and the measured signal (sample value) is taken as a measure of the

amount of analyte in the sample. To transfer the measurement signal to actual amounts of analyte the signal is usually compared to the corresponding signal (calibrator value) of known standard amounts of analyte (calibrators).

- 5 In connection with the present invention a new calibrator system has been developed which applied to the present invention constitutes a best embodiment.

This separate invention means that the used calibrator in advance has been anchored to a matrix (matrix calibrator), preferably of the same type as the one utilized for sample run. When measuring the calibrator values matrix calibrator is allowed to bind to Reactant* and then the measurement signal from Reactant* is measured in a way known per se. By utilizing different amounts of matrix calibrator a series of calibrator values may be obtained corresponding to different pre-determined amounts of analyte in sample (standard amounts, dose response curve, calibration curve).

20 Instead of anchoring the calibrator in advance to the matrix, a reactant capable of binding the calibrator may be anchored and the calibrator is then added in connection with the determination of calibrator value. When a calibrator binder is bound to the matrix, the calibrator 25 may either be movably (diffusively) pre-deposited in the matrix in a zone or area separated from the detection zone, or may be added together with or separately from the sample.

30 Applied to the present invention our new calibrator system primarily involves that the transport flow passes one or more zones with a calibrator firmly anchored to the matrix in the respective calibrator zone (KZ).

35 Anchoring of a calibrator or a calibrator binder to the matrix in a calibrator zone may be performed according to the same principles as for anchoring of Reactant I to a detection zone. The calibrator binder is usually one member

of a specific binding pair (reactant pair), the other member of the binding pair being coupled or conjugated to the calibrator substance. Examples of such specific binding pairs have been mentioned above in connection with the 5 description of the Capturer.

Calibrator zones should be located downstream of the application zone for liquid, intended for transport of Reactant*. In relation to the detection zone (DZ), the 10 calibrator zone is preferably located upstream.

Our invention relating to calibrators is described in detail in our co-pending PCT application with the title "A method using a new calibrator and a device and test kit 15 including the calibrator" (based on SE 9704933-2). This application is incorporated herein by reference.

A second main aspect of the invention

This aspect of the invention is a kit exhibiting (a) an 20 analytically detectable biospecific affinity reactant (Reactant*), in which the label group is particles, together with (b) a flow matrix having a detection zone in which a Capturer is firmly anchored via particles which 25 preferably are smaller than the smallest inner dimension of the flow channels. Relevant particles and flow channels are according to what has been mentioned above. The flow matrix may exhibit application zones, pre-deposited reactants etc. according to the above.

30 The invention is illustrated in the experimental part and defined in the claims.

EXAMPLE 1: COMPARISON BETWEEN BIRCH ALLERGEN BOUND VIA PARTICLES OR DIRECTLY ADSORBED TO THE DETECTION ZONE

35 The example is based on determination of IgE specific to birch allergen. To show the strength of the invention the response obtained with a number of patient samples is

compared in a test variant where 1) the allergen extract has been coupled covalently to polystyrene particles coated with phenyldextran deposited in the detection zone with 2) allergen extract directly deposited and passively bound to
5 a nitrocellulose membrane.

Methods and materials

Adsorption of phenyldextran to polystyrene particles:

Phenyldextran (substitution degree: 1 phenyl group on each
10 fifth monosaccharide unit = 20%, Mw dextran 40,000,
Pharmacia Biotech AB, Uppsala, Sweden) dissolved in
deionized water to various concentrations was adsorbed with
stirring to polystyrene particles (0,49 µm, Bangs
Laboratories): 1) 4-5 mg/ml, 8-10% particle suspension, RT
15 0,5 h; 2) 5 mg/ml, 5% particle suspension, RT, 1 h; 3) 20
mg/ml, 2% particle suspension, overnight. The particles
were then washed twice in deionized water. The particle
suspension was centrifuged between each incubation and wash
(12,100 g, 30 minutes, Beckman J2-21).
20

Extraction of t3 (birch pollen, Betula verrucosa): 1 part
(weight) of birch pollen (Allergon, Sweden) was extracted
with 10 parts (volume) of 0,1 M of phosphate buffer, pH
7.4. The extraction was continued for 2 h on a shaker table
25 (200 pulses/minute) at +4°C. The extract was centrifuged at
4000 rpm for 1,75 h. After filtration the t3-extract was
applied to a PD-10 column (Pharmacia Biotech AB, Sweden)
and eluted in 0,1 M NaHCO₃, pH 8.5. The t3-eluate
(designated: t3-extract 1/14) was taken to amino acid
30 analysis for determination of the total level of protein.

Coupling of t3-extract to polystyrene particles (t3-particles): t3-extract was coupled to phenyldextran coated
polystyrene particles with CDAP (1-cyano-4-dimethylamino-
35 pyridinium bromide) (Kohn J and Wilchek M, FEBS Letters
154(1) (1983) 209-210).

Polystyrene particles (2128 mg) coated with phenyldextran in 30% (by volume) acetone, 2% particle suspension, were activated with 954 mg CDAP (100 mg/ml in 30% acetone) and 7.63 ml of 0,2 M triethylamine (TEA, Riedel-de Haen, 5 Germany). CDAP was added with stirring and TEA was added dropwise for 90 seconds and stirring for a total of 120 s. The reaction was stopped by addition of 30% acetone (4 fold the volume) and centrifugation at 12,400 g for 35 minutes. The particles were washed once with deionized water.

10

640 ml of t3-extract 1/14 in 0,1 M NaHCO₃, pH 8.5, were added to the activated particles and the coupling reaction was performed for 1 h on a shaker table. The suspension was centrifuged and decanted before the particles were 15 deactivated with 0.05 M aspartic acid and 0.05 M glutamic acid in 0.1 M NaHCO₃, pH 8.5. Incubation was effected on a shaker table overnight at +4°C. The particles were washed by centrifugation twice with 50 mM NaPO₄, 0.05% NaN₃, pH 7.4.

20

The concentration of particles was determined by a spectrophotometer at 600 nm with uncoated polystyrene particles as a reference. t3-coupled polystyrene particles were taken to amino acid analysis for determination of the 25 total level of protein.

Deposition of t3-extract and t3-particles on membrane (detection zone): To sheets of nitrocellulose with a polyester backing (Whatman, 8 µm, width 5 cm) zones of t3-extract 1/14 were applied with Linear Stripper (IVEK Corporation) with a flow of 1 µl/s and 1 µl/cm. The t3-extract 1/14 was deposited undiluted and also diluted 1:1 in 0.1 M NaHCO₃, pH 8.5 (t3-extract 1/28). T3-particles were diluted to 4% particle level in 50 mM NaPO₄, 6% 35 lactose, 0.05% NaN₃, pH 7.4.

20

Sheets with deposited material were dried for 1 hour at 30°C. The sheets were cut into strips with a width of 0.5 cm (Matrix 1201 Membrane Cutter, Kinematics Automation).

- 5 Carbon particle conjugate (Reactant*): Monoclonal anti-human IgE antibody (anti-hIgE) was adsorbed to carbon particles (sp100, < 1 µm, Degussa, Germany) according to WO 96/22532. The final suspension diluted in test buffer contained 300 µg/ml carbon particles.

10

- Test methodology: Strips were mounted on a surface inclined about 16° from the bench plane. Sucking membranes (width 3 cm, Whatman, 17 Chr) were placed 0.5 cm into the end of the strip. To obtain a constant pressure metal weights were put 15 on the sucking membranes.

Samples and reagents were pipetted in the order below. Each sample and reagent volume was allowed to migrate into the membrane before the subsequent volume was pipetted.

20

- 1) 30 µl of test buffer (0.1 M Tris-HCl, 0.6 M NaCl, 10% sucrose, 3% bovine serum albumin, 0.05% bovine gammaglobulin, pH 7.4)
- 2) 30 µl serum sample
- 25 3) 20 µl of test buffer (the same as in step 1)
- 4) 20 µl of carbon particle conjugate (anti-hIgE antibody adsorbed to carbon particles, 300 µg/ml, diluted in test buffer)
- 5) 2 x 30 µl of test buffer
- 30 6) The carbon blackening of the detection zone was measured as absorbance with Ultroncan XL, Enhanced Laser Densitometer (LKB).

RESULTS

Amount of protein in the detection zone

Table 1 Deposited amount of t3 in the detection zone

5

Deposition solution/ suspension	Amount of protein in reaction zone per 0.5 cm strip (ng)
t3-extract 1/14	410
t3-extract 1/28	205
t3-coupled particles (4%)	226

Table 2

Lateral immuno-chromatography with (i) directly adsorbed
 10 t3-extract and (ii) t3-coupled particles in the detection
 zone. Uptake of t3 positive and negative serum samples,
 determined concerning concentration with Pharmacia CAP
 system (Pharmacia & Upjohn Diagnostics AB, Sweden).

Deposition solution/ suspension	35534 (1.8 KU/L)	35696 (3.1 KU/L)	35711 (29.4 KU/L)	36429 (neg, < 0.35 KU/L)
t3-extract 1/14	5*	6	3	0
t3-extract 1/28	5	0	0	0
4% t3-coupled particles	106	64	474	18

15

* = Absorbance (x1000) in the reaction zone when the label
 has been bound.

Conclusion

The experiments show that the same amount of birch allergen deposited in the form of coupled particles gives significantly higher binding of birch-specific IgE-
5 antibodies as compared to when the allergen is deposited directly on the membrane.

In similar experiments different monodisperse polystyrene particles (Bangs Laboratories) were used as anchoring
10 particles and instead of carbon particles, different diameters of fluorescent polystyrene were used. The diameters of the anchoring particles varied in the different experiments in the interval 0.28-3 µm. The diameters of the label particles varied in the different
15 experiments in the interval 0.1-0.5 µm. The results followed generally the results for carbon particles as presented in detail above.

20 **EXAMPLE 2: DETERMINATION OF BIRCH-SPECIFIC IgE WITH TEST VARIANT WHERE ALLERGENS HAVE BEEN PRE-DEPOSITED IN THE APPLICATION ZONE**

Methods and materials

25 Biotinylation of birch pollen allergen: Extraction of t3 (birch pollen; *Betula verrucosa*) was performed as described previously except that the centrifuged and filtrated solution was applied to a PD-10 column and eluted into deionized water. The t3-eluate was freeze-dried (LSL
30 SECFROID, LYOLAB F, pump: LEYBOLD TRIVAC D8B).

Freeze-dried t3-material was dissolved in 0.15 M KPO₄, 0.15 M NaCl, pH 7.8. Determination of content was performed by aminoacid analysis. To the material was added ¹²⁵I-labelled
35 t3 and the mixture was applied to a PD-10 column equilibrated with 25 ml of 0.15 M KPO₄, 0.15 M NaCl, pH 7.8. Biotinylation of t3-allergen was carried out according to recommended conditions from the supplier (Pierce). To 3

mg of eluted t3-extract (2.0 ml) was then added 0.138 ml of biotin-LC-Sulfo-NHS (3.59 mM, Pierce), and incubation was performed on a shaker for 1 hour at room temperature. The coupling reaction was stopped by the addition of 50 µL of 2 M glycine. The extract was then applied to a gel filtration column PD-10 equilibrated with 50 mM NaPO₄, 0.15 M NaCl, pH 7.4. Yields and final protein concentration were determined from the obtained radioactivity.

10 Coupling of streptavidin to polystyrene particles:

Streptavidin (Molecular Probes) was covalently coupled to phenyldextran-adsorbed polystyrene particles with CDAP (1-cyano-4-dimethylamino-pyridinium bromide) (Kohn J and Wilchek M, FEBS Letters 154(1) (1983) 209-210).

15

Desalting and buffer change of streptavidin was performed by gel filtration (PD-10) in NaHCO₃, 0.1 M, pH 8.5. 600 mg of phenyldextran-coated polystyrene particles in a 2 % solution in 30 % (by volume) acetone were activated by 4.5 ml of CDAP (0.44 M) and 3.6 ml of TEA (0.2 M triethylamine, Riedel-deHaën). CDAP was added with stirring for 60 seconds and TEA for 120 seconds. The particles were then washed with 30 % (by volume) acetone and centrifuged at 12,100 g (25 minutes, Beckman, J-21, JA-20, 10,000 rpm).

25

20.6 mg of streptavidin were coupled to 350 mg of activated particles with incubation on a shaker for 1.5 hours at +4°C. The particles were then centrifuged before deactivation was carried out with 0.05 M glutamic acid and 30 0.05 M aspartic acid in NaHCO₃ buffer. Incubation was effected with stirring overnight at +4°C. The coupled particles were then washed twice with 50 mM NaPO₄, 0.05 % NaN₃, pH 7.4.

35 The particle concentration was determined spectrophotometrically at A 600 nm with untreated particles as reference.

Deposition of streptavidin-coupled particles on nitrocellulose membranes: To sheets of nitrocellulose with a polyester backing (Whatman, 8 µm, 5 cm width) zones of 5 streptavidin-coupled particles diluted to 1 % particle content in 10 mM NaPO₄, 5 % sucrose, 5 % dextran 5000, pH 7.4, were applied with a Linear Stripper (IVEK Corporation).

The deposition flow was 2.5 µl/cm and the rate 20 mm/sec. 10 The deposits were dried for 1 hour at 30°C, whereupon the sheets were cut to 0.5 cm wide strips (Matrix 1201 Membrane Cutter, Kinematics Automation).

Deposition of biotinylated allergen on filter paper: 10 x 5 15 mm filters were cut from filter papers (Whatman 3). 10 µl of biotinylated t3 (77 ng) in 50 mM phosphate buffer, pH 7.4, BSA 6 %, were dispensed to the filters, and the filters were dried at 30°C for 45 minutes.

20 Coupling of anti-hIgE antibodies to detection particles: Antibodies to hIgE cleaved with pepsin to fab'2 fragments were coupled to fluorescent polystyrene particles having aldehyde groups on their surface (Molecular Probes C-17177 TransFluoSpheres, aldehyde-sulphate microspheres, 0.1 µm, 25 633/720, 2 % solids). 23 mg of antibody were coupled to 66 mg of particles in 50 mM NaPO₄ buffer, pH 6, overnight at room temperature. Then 205 µL of NaCNBH₄ (5 M) were added to reduce the coupling for 3 hours at room temperature. After centrifugation at 20,800 x g (50 minutes in Eppendorf 30 5417R, 14,000 rpm), deactivation was performed in 0.05 M glutamic acid and 0.05 M aspartic acid in deionized water, pH 6.5, overnight with stirring at room temperature. Centrifugation was then carried out at 20,800 x g (50 min). After blocking with 0.2 % BSA in 50 mM NaPO₄, pH 7.4, with 35 0.05 % NaN₃ and incubation overnight at +4°C, centrifugation was performed again at 20,800 x g (50 min).

Washing twice with and storage in blocking buffer was then done. The particle concentration was determined in a fluorimeter (Perkin-Elmer LS50B) with a standard curve prepared with the original particle. Coupled protein 5 concentration was determined by having radioactive anti-hIgE present during the coupling.

Test procedure: Strips were mounted to a surface inclined about 16° from the bench plane. Sucking membranes (3.5 cm 10 width, Schleicher & Schuell, GB004) were placed 0.5 cm into the upper end of the strip. To obtain constant pressure, metal weights were placed on the sucking membranes. Samples and reagents were then pipetted successively as described below. Each sample and reagent volume was sucked into the 15 membrane before the following volume was pipetted.

- 1) Prewash with 30 µl of 50 mM NaPO₄, 0.15 M NaCl, pH 7.4.
- 2) A filter with predeposited biotinylated IgE was placed at the bottom of the strip.
- 20 3) 30 µl of serum were pipetted to each filter.
- 4) 20 µl of test buffer (0.1 NaPO₄, 0.15 M NaCl, 10 % sucrose, 3 % BSA, 0.05 % bovine gammaglobulin, 0.05 % NaN₃, pH 7.4) were added to the filter.
- 5) The allergen filter was removed.
- 25 6) 20 µl of detection conjugate (75 µg/ml) diluted in test buffer.
- 7) 2 x 30 µl of test buffer.
- 8) The fluorescence of the detection zone was measured as a response area (Vmm) with a scanning red laser fluorometer
- 30 (635 nm).

Selected serum samples included negative, weakly positive and a high positive serum.

Results

Sample	IgE conc.	Group	Response area
	(KU/L)		(Vmm)
35517	0.7	weakly pos.	0.083
35713	0.8	weakly pos.	0.037
35803	0.9	weakly pos.	0.361
35805	1.1	weakly pos.	0.166
37692	neg.	neg.	0.001
35592	neg.	neg.	0.096
35593	neg.	neg.	0.006
35599	neg.	neg.	0.002
35716	54	pos.	2.507

- 5 The results show that the principle of predeposited allergens (or antigens) in the application zone and a general binder in the reaction zone functions well.

CLAIMS

1. A method associated with analytical methods in a flow matrix, which methods utilize biospecific affinity reactions to detect an analyte in a sample, and which comprises:

- 5 i. allowing the sample (analyte) and an analytically detectable reactant (Reactant*) migrate through flow channels in a flow matrix to a detection zone (DZ) located in the matrix, in which there is a firmly anchored biospecific affinity reactant (Capturer), wherein
- 10 ii. Reactant* is captured in the detection zone (DZ) in an amount, being related to the amount of analyte in the sample,
- 15 **characterized** in that
- 20 A) Reactant* has particles as an analytically detectable group, and
- 25 B) the Capturer is anchored to the matrix via immobilized particles, which preferably exhibit hydrophilic groups on their surface.

2. The method according to claim 1, **characterized** in that the flow occurs laterally in the matrix.

25 3. The method according to claim 1 or 2, **characterized** in that the flow is driven by capillary forces.

30 4. The method according to any of the claims 1-3, **characterized** in that the Capturer is capable of binding via biospecific affinity a reactant which in turn binds analyte biospecifically.

35 5. The method according to claim 4, **characterized** in that said reactant is applied with the sample or is predeposited in the matrix upstream of the detection

zone (DZ) such that the reactant can react with analyte before reaching the detection zone (DZ).

6. The method according to any of claims 1-5,
5 **characterized** in that the particles anchoring the Capturer have a size which is smaller than the smallest inner dimension of the flow channels of the matrix.
7. The method according to any of the claims 1-6,
10 **characterized** in that the particles, which anchor the Capturer, have a size being in the range of 0.1-1000 µm, preferably the range of 0.1-100 µm.
8. The method according to any of the claims 1-7,
15 **characterized** in that the label particles have a diameter in the range of 0.01-5 µm.
9. The method according to any of the claims 1-8,
20 **characterized** in that the flow channels have the smallest inner dimension in the range of 0.4-1000 µm, preferably 0.4-100 µm.
10. The method according to any of the claims 1-9,
25 **characterized** in that the label particles are fluorescent or coloured.
11. The method according to any of the claims 1-10,
30 **characterized** in that Reactant* is predeposited in the matrix upstream of the detection zone (DZ) and preferably upstream of the sample application site.
12. The method according to any of the claims 1-11,
35 **characterized** in that the particles, which anchor the Capturer to the matrix, are a synthetic polymer or a semisynthetic polymer or a biopolymer which on its surface exhibits hydrophilic groups.

13. The method according to any of the claims 1-12,
characterized in that the determination method is of
sandwich type in which Reactant* is captured in the
5 detection zone (DZ) by formation of the ternary complex
Reactant'---analyte---Reactant*, wherein Reactant' and
Reactant* are able to simultaneously bind analyte
biospecifically and Reactant' is the firmly anchored
Capturer or a reactant to which the Capturer may bind
10 via biospecific affinity.
14. The method according to claim 13, characterized in that
the analyte is an antibody with specificity for either
Reactant' or Reactant*, and that
15
- a) Reactant' is an antigen/hapten and Reactant* is an
antibody directed to a constant antibody region on
the analyte, when the antibody specificity of the
analyte is directed to Reactant', or
20
- b) Reactant* is an antigen/hapten and Reactant' is an
antibody directed to a constant antibody region on
the analyte, when the antibody specificity of the
analyte is directed to Reactant'.
25
15. The method according to claim 13, characterized in that
the analyte is an antigen and Reactant' and Reactant*
are antibodies with specificity for epitopes on the
analyte.
30
16. The method according to any of the claims 13-14,
characterized in that the analyte is of IgE class
directed to an allergen.
35 17. The method according to any one of the claims 1-16,
characterized in that the determination method is

performed in connection with diagnosing allergy or autoimmune disease.

18. A test kit for performing analytical methods in a flow

5 matrix, which methods utilize biospecific affinity reactions to detect an analyte in a sample, which kit comprises (i) a flow matrix having a detection zone (DZ), in which there is a firmly anchored biospecific affinity reactant (Capturer), and (ii) an analytically 10 detectable reactant (Reactant*),

characterized in that

A) Reactant* has particles as an analytically detectable group, and

15 B) the Capturer is anchored to the matrix via immobilized particles, which preferably exhibit hydrophilic groups on their surface.

19. The kit according to claim 18, **characterized** in that

the matrix is a lateral flow matrix.

20

20. The kit according to claim 18 or 19, **characterized** in that the flow in the matrix is driven by capillary forces.

25 21. The kit according to any of the claims 18-20, **characterized** in that the Capturer is capable of binding via biospecific affinity a reactant which in turn binds analyte biospecifically.

30 22. The kit according to claim 21, **characterized** in that said reactant is applied with the sample or is predeposited in the matrix upstream of the detection zone (DZ) such that the reactant can react with analyte before reaching the detection zone (DZ).

35

23. The kit according to any one of claims 18-22, **characterized** in that the particles anchoring the

Capturer have a size which is smaller than the smallest inner dimension of the flow channels of the matrix.

24. The kit according to any of the claims 18-23,
5 **characterized** in that the particles, which anchor the Capturer, have a size being in the range of 0.1-1000 µm, preferably the range of 0.1-100 µm.
25. The kit according to any of the claims 18-24,
10 **characterized** in that the label particles have a diameter in the range of 0.01-5 µm.
26. The kit according to any of the claims 18-25,
15 **characterized** in that the flow channels have the smallest inner dimension in the range of 0.4-1000 µm, preferably 0.4-100 µm.
27. The kit according to any of the claims 18-26,
20 **characterized** in that the label particles are fluorescent or coloured.
28. The kit according to any of the claims 18-27,
25 **characterized** in that Reactant* is predeposited in the matrix upstream of the detection zone (DZ) and preferably upstream of the sample application site.
29. The kit according to any of the claims 18-28,
30 **characterized** in that the particles, which anchor the Capturer to the matrix, are a synthetic polymer or a semisynthetic polymer or a biopolymer which on its surface exhibits hydrophilic groups.
30. The kit according to any of the claims 18-29,
35 **characterized** in that the kit is intended for a determination method of sandwich type in which Reactant* is captured in the detection zone (DZ) by

formation of the ternary complex Reactant'---analyte---Reactant*, wherein Reactant' and Reactant* are able to simultaneously bind analyte biospecifically and Reactant' is the firmly anchored Capturer or a reactant to which the Capturer may bind via biospecific affinity.

5 31. The kit according to claim 30, **characterized** in that the analyte is an antibody with specificity for either 10 Reactant' or Reactant*, and that

- 10 a) Reactant' is an antigen/hapten and Reactant* is an antibody directed to a constant antibody region on the analyte, when the antibody specificity of the analyte is directed to Reactant', or
15 b) Reactant* is an antigen/hapten and Reactant' is an antibody directed to a constant antibody region on the analyte, when the antibody specificity of the analyte is directed to Reactant*.

20 32. The kit according to claim 30, **characterized** in that the analyte is an antigen and Reactant' and Reactant* are antibodies with a specificity for epitopes on the analyte.

25 33. The kit according to claim 30 or 31, **characterized** in that the analyte is of IgE class directed to an allergen.

30 34. The kit according to any of the claims 18-33, **characterized** in that the determination method is performed in connection with diagnosing allergy or autoimmune disease.

DECLARATION
and
POWER OF ATTORNEY

U.S. NATIONAL PHASE OF INTERNATIONAL APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **Analytical Method Using Particles and Test Kit for Performing the Method**, the specification of which was filed as International Application No. PCT/SE98/02462 on December 30, 1998,

[] and was amended under Article 19 on _____
 (if applicable)

[] and was amended under Article 34 on _____
 (if applicable)

[X] and was assigned U.S. Application Serial No. 09/582,808, and was
 amended on June 30, 2000.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits and/or U.S. Provisional application priority benefits under Title 35, United States Code, §119 of any foreign application(s) or U.S. Provisional applications for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign and U.S. Provisional Application(s)			Priority Claimed	
Number	Country	Day/Month/Year Filed	Yes	No
9704935-7	Sweden	December 30, 1997	X	

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulation, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby appoint Holly D. Kozlowski, Registration No. 30,468; Ronald J. Snyder, Registration No. 31,062; James D. Liles, Registration No. 28,320; Lynda E. Roesch, Registration No. 29,696; Phillip A. Rotman II, Registration No. 38,290; Martin J. Miller, Registration No. 35,953; Victor C. Moreno, Registration No. 40,732; Jackie A. Zurcher, Registration No. 42,251; John V. Harmeyer, Registration No. 41,845; Scott N. Barker, Registration No. 42,292; Geoffrey L. Oberhaus, Registration No. 42,955; Joseph P. Mehrle, Registration No. P-45,535; John P. Colbert, Registration No. P-45,765; and Stephen S. Wentsler, Registration No. P-46,403, my attorneys, c/o Dinsmore & Shohl LLP, 1900 Chemed Center, 255 East Fifth Street, Cincinnati, Ohio 45202 (513) 977-8200, with full power in each of them, of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

The undersigned hereby authorizes the above-named U.S. attorneys to accept and follow instructions from **Pharmacia & Upjohn AB** as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the undersigned and the aforementioned U.S. attorneys. In the event of a change in the firm or persons from whom instructions may be taken, the aforementioned U.S. attorneys will be so notified in writing by the undersigned.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: IB MENDEL HARTVIG

Inventor's signature IB Menzel Hartvig

15/9 2000

Date

Residence: Rabeniusvägen 28, S-756 55 Uppsala, Sweden
Citizenship: Sweden

Post Office Address: Rabeniusvägen 28, S-756 55 Uppsala, Sweden

SQX

3-00

Full name of second inventor: Lena VINTERBÄCK

Inventor's signature

18/9 2000

Date

Residence: Gläntvägen 19A, S-757 56 Uppsala, Sweden

Citizenship: Sweden

Post Office Address: Gläntvägen 19A, S-757 56 Uppsala, Sweden

Full name of third inventor: Ann JONSSON

Inventor's signature

15/9 2000

Date

Residence: Norrtäljegatan 5B, S-753 27 Uppsala, Sweden

Citizenship: Sweden

Post Office Address: Norrtäljegatan 5B, S-753 27 Uppsala, Sweden

Full name of fourth inventor: Jörgen GUSTAFSSON

Inventor's signature

19/9 2000

Date

Residence: Tunagatan 7D, S-753 37 Uppsala, Sweden

Citizenship: Sweden

Post Office Address: Tunagatan 7D, S-753 37 Uppsala, Sweden